PHAS News and Press, PhaseBio Pharmaceuticals Inc. From 03/08/22

Manufacturing of bentracimab drug substance and drug product Process Performance Qualification (PPQ) batches has been completed PhaseBio remains on track to submit bentracimab Biologics License Application (BLA) in mid-2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq:...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discuss...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Phase 2b trial of bentracimab, which was conducted in healthy, older v...

PhaseBio Pharmaceuticals (NASDAQ:PHAS) falls 5.6% premarket following an announcement that it is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH) due to COVID-19 impacts on manufacturing, associated drug supply and the rat...

PhaseBio (NASDAQ:PHAS) has ended early a phase 2b trial of pemziviptadil, its pulmonary arterial hypertension candidate, due to COVID-19 impacts. The company says the pandemic has impacted manufacturing, associated drug supply, and the rate of enrollment in the study. “With the co...

Results previously presented in a Late-Breaking Science Session at the American Heart Association’s 2021 Scientific Sessions Global Phase 3 trial of bentracimab achieved both primary reversal endpoint and co-primary endpoint of clinical hemostasis Bentracimab ha...

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has appointed Jonathan Birchall as Chief Commercial Officer. Prior to this appointment, Birchall was Vice President and U.S. Head of Genentech's thrombolytics franchise. In the new role, Birchall lead PhaseBio's efforts to build a critical-care focused c...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer. ȁ...

PhaseBio Pharmaceuticals (PHAS -8.0%) and its co-development partner SFJ Pharmaceuticals shared data from an ongoing pivotal Phase 3 trial for the company’s lead product candidate, bentracimab. The 150-patient study was designed to evaluate bentracimab in the reversal of ticagrelo...

Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of clinical hemostasis achieved in greater than 90% of patients ...